Orphan Disease Market Share, Size, Key Players, Trends, Competitive And Regional Forecast To 2030
Orphan Disease Market Overview
Orphan
diseases are also referred to as rare diseases. Despite the low market
interest, treatment demand continues to grow for orphan diseases. Orphan
diseases represent a very small percentage of the global population. However,
prevalence rate has increased considerably in recent years. Most orphan
diseases are genetic and may remain in patient throughout their life. While
many orphan diseases are low-risk and do not threaten life, some may have
severe impact on the health. Approximately 7000 different rare diseases are
listed, however, no exact figure is available.
The market for
orphan diseases is growing swiftly. Rising level of awareness and increased
funding is reflecting favourably on the market. According to a study conducted
by market research future, the global Orphan Disease Market is projected to demonstrate a compound annual
growth rate (CAGR) of 10.7% during the forecast period (2022-2030). The market
size is expected to surpass USD 328.5 Bn by the year 2030.
Demand for
orphan drugs has grown substantially in recent years. Many governments all
around the world are financially incentivising drugs through regulations. A
data released by National Organization for Rare Disorders (NORD), reveals that
in 2018, nearly 30 Mn Americans suffer from 7,000 rare diseases. More and more
initiatives are taken towards improving orphan disease care. This is notable
for advanced countries such as the U.S., Japan and EU countries. Over the past
couple years, orphan drug sales have doubled
Orphan Disease Market Segmentation
MRFR’s report includes a
detailed segmental analysis of the market based on disease, treatment and end
user.
On the basis of disease,
the market has been segmented into genetic disorders, cancer, cardiovascular
diseases, respiratory disorders, autoimmune disorders, neurological disorders,
blood disorders, eye disorders, digestive disorders, growth disorder and
others. On the basis of treatment, the market has been segmented into drug
therapy, cell therapy, gene therapy and others. Based on end user, the market
has been segmented into research laboratory, hospital and clinics and others.
Orphan Disease Market Regional
Analysis
Depending on geographic region, Orphan diseases Market is
segmented into four key regions: Americas, Europe, Asia-Pacific, and Middle
East & Africa. Considering the global scenario of the market, North America
comprise largest market share in Orphan diseases. Moreover the European market
is also growing continuously and slowly catching up with the American market in
the near future. On the other hand, Asia-Pacific market is expected to grow at
the fastest pace in the Orphan diseases segment during the forecasted period.
Rest of the World is likely to have a limited but steady growth in the market.
Competitive Landscape
global orphan
diseases market Players include F. Hoffmann-La Roche Ltd (Switzerland),
Vertex Pharmaceuticals Incorporated (US), CELGENE CORPORATION (US), Merck &
Co., Inc (US), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US),
AbbVie Inc. (US), Sanofi (French), Alexion (US), GlaxoSmithKline plc. (UK) and
Pfizer Inc. (US).
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1
628 258 0071
Email:
sales@marketresearchfuture.com
.jpg)
Comments
Post a Comment